{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:34:12Z","timestamp":1784673252209,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Since homologous recombination deficiency (HRD) is relatively uncommon in pancreatic cancer (PC), its impact on time-to-treatment failure (TTF) among patients undergoing systemic chemotherapy for unresectable and recurrent PC remains uncertain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Among patients with unresectable and recurrent PC enrolled in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database by July 2023, a total of 1394 patients who underwent first-line chemotherapy with either gemcitabine plus nab-paclitaxel (GnP) or FOLFIRINOX (FFX) and received tissue-based CGP tests after disease progression were included in this study. HRD was defined as the presence of germline or somatic genetic mutations in homologous recombination repair (HRR)-related genes such as <jats:italic>ATM, BARD1, BRIP1, BRCA1\/2, CHEK2, CDK12, PALB, and RAD51C\/D<\/jats:italic>. We investigated the correlation between HRD and TTF among patients treated with GnP and FFX.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>First-line chemotherapy consisted of GnP in 69% of the cases and FFX in 31%. The CGP tests used were NCC OncoPanel and FoundationOne CDx in 26% and 74%, respectively. HRR-related genetic abnormalities were identified in 107 patients (7.6%): <jats:italic>BRCA2<\/jats:italic> (<jats:italic>n<\/jats:italic>\u2009=\u200951), <jats:italic>ATM<\/jats:italic> (<jats:italic>n<\/jats:italic>\u2009=\u200934), <jats:italic>BRCA1<\/jats:italic> (<jats:italic>n<\/jats:italic>\u2009=\u20099), <jats:italic>PALB2<\/jats:italic> (<jats:italic>n<\/jats:italic>\u2009=\u20099), among others. In the GnP cohort, the median TTF was comparable between the HRD and non-HRD groups (5.3 vs 4.6\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.44). Conversely, in the FFX cohort, it was significantly longer in the HRD group compared to the non-HRD group (7.3 vs. 4.7\u00a0months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings suggest that HRR-related genetic abnormalities might be predictive of TTF in platinum-based chemotherapy for PC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00535-024-02173-0","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T05:59:02Z","timestamp":1732168742000},"page":"247-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT database"],"prefix":"10.1007","volume":"60","author":[{"given":"Kazunaga","family":"Ishigaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurie","family":"Tokito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-3100","authenticated-orcid":false,"given":"Naminatsu","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Takaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensaku","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Miyabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Kage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"2173_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00291","author":"H Ebi","year":"2019","unstructured":"Ebi H, Bando H. Precision oncology and the universal health coverage system in Japan. JCO Precis Oncol. 2019. https:\/\/doi.org\/10.1200\/PO.19.00291.","journal-title":"JCO Precis Oncol"},{"key":"2173_CR2","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1111\/cas.15517","volume":"113","author":"K Sunami","year":"2022","unstructured":"Sunami K, Naito Y, Komine K, et al. Chronological improvement in precision oncology implementation in Japan. Cancer Sci. 2022;113:3995\u20134000.","journal-title":"Cancer Sci"},{"key":"2173_CR3","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","volume":"12","author":"T Kohno","year":"2022","unstructured":"Kohno T, Kato M, Kohsaka S, et al. C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan. Cancer Discov. 2022;12:2509\u201315.","journal-title":"Cancer Discov"},{"key":"2173_CR4","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.3390\/cancers14143476","volume":"14","author":"R Noji","year":"2022","unstructured":"Noji R, Tohyama K, Kugimoto T, et al. Comprehensive genomic profiling reveals clinical associations in response to immune therapy in head and neck cancer. Cancers (Basel). 2022;14:3476.","journal-title":"Cancers (Basel)"},{"key":"2173_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/cancers16010136","volume":"16","author":"Q Xi","year":"2023","unstructured":"Xi Q, Kage H, Ogawa M, et al. Genomic landscape of endometrial, ovarian, and cervical cancers in Japan from the database in the center for cancer genomics and advanced Therapeutics. Cancers (Basel). 2023;16:136.","journal-title":"Cancers (Basel)"},{"key":"2173_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101627","volume":"8","author":"K Kurokawa","year":"2023","unstructured":"Kurokawa K, Shukuya T, Greenstein RA, et al. Genomic characterization of thymic epithelial tumors in a real-world dataset. ESMO Open. 2023;8: 101627.","journal-title":"ESMO Open"},{"key":"2173_CR7","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/hed.27540","volume":"45","author":"Y Saito","year":"2023","unstructured":"Saito Y, Kage H, Kobayashi K, et al. TERT promoter mutation positive oral cavity carcinomas, a clinically and genetically distinct subgroup of head and neck squamous cell carcinomas. Head Neck. 2023;45:3107\u201318.","journal-title":"Head Neck"},{"key":"2173_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00535-023-01986-9","volume":"58","author":"T Sakakida","year":"2023","unstructured":"Sakakida T, Ishikawa T, Doi T, et al. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. J Gastroenterol. 2023;58:575\u201385.","journal-title":"J Gastroenterol"},{"key":"2173_CR9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/jjco\/hyad066","volume":"53","author":"K Kobayashi","year":"2023","unstructured":"Kobayashi K, Saito Y, Kage H, et al. CDK12 alterations and ARID1A mutations are predictors of poor prognosis and therapeutic targets in high-grade salivary gland carcinoma: analysis of the National Genomic Profiling Database. Jpn J Clin Oncol. 2023;53:798\u2013807.","journal-title":"Jpn J Clin Oncol"},{"key":"2173_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11060-023-04411-6","volume":"164","author":"R Otani","year":"2023","unstructured":"Otani R, Ikegami M, Yamada R, et al. PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort. J Neurooncol. 2023;164:221\u20139.","journal-title":"J Neurooncol"},{"key":"2173_CR11","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3390\/medicina59122111","volume":"59","author":"T Naito","year":"2023","unstructured":"Naito T, Noji R, Kugimoto T, et al. The efficacy of immunotherapy and clinical utility of comprehensive genomic profiling in adenoid cystic carcinoma of head and neck. Medicina (Kaunas). 2023;59:2111.","journal-title":"Medicina (Kaunas)"},{"key":"2173_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00535-023-02058-8","volume":"59","author":"T Sakakida","year":"2024","unstructured":"Sakakida T, Ishikawa T, Doi T, et al. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database. J Gastroenterol. 2024;59:145\u201356.","journal-title":"J Gastroenterol"},{"key":"2173_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/gcc.23182","volume":"62","author":"H Kobayashi","year":"2023","unstructured":"Kobayashi H, Zhang L, Okajima K, et al. BRAF mutations and concurrent alterations in patients with soft tissue sarcoma. Genes Chromosomes Cancer. 2023;62:648\u201354.","journal-title":"Genes Chromosomes Cancer"},{"key":"2173_CR14","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"2173_CR15","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"2173_CR16","doi-asserted-by":"publisher","first-page":"S894","DOI":"10.1016\/j.annonc.2023.09.2565","volume":"34","author":"AOM Ohba","year":"2023","unstructured":"Ohba AOM, Ogawa G. 1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicentred, randomized, open-label, three-arm, phase II\/III trial. Ann Oncol. 2023;34:S894.","journal-title":"Ann Oncol"},{"key":"2173_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"key":"2173_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000942","volume":"5","author":"A Seeber","year":"2020","unstructured":"Seeber A, Zimmer K, Kocher F, et al. Molecular characteristics of BRCA1\/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO open. 2020;5: e000942.","journal-title":"ESMO open"},{"key":"2173_CR19","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O'Reilly","year":"2020","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J Clin Oncol. 2020;38:1378\u201388.","journal-title":"J Clin Oncol"},{"key":"2173_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122:333\u20139.","journal-title":"Br J Cancer"},{"key":"2173_CR21","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/cancers15041299","volume":"15","author":"L Galland","year":"2023","unstructured":"Galland L, Roussot N, Desmoulins I, et al. Clinical utility of genomic tests evaluating homologous recombination repair deficiency (HRD) for treatment decisions in early and metastatic breast cancer. Cancers (Basel). 2023;15:1299.","journal-title":"Cancers (Basel)"},{"key":"2173_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","volume":"34","author":"Z Kuzbari","year":"2023","unstructured":"Kuzbari Z, Bandlamudi C, Loveday C, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol. 2023;34:215\u201327.","journal-title":"Ann Oncol"},{"key":"2173_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000578","volume":"5","author":"I Pokataev","year":"2020","unstructured":"Pokataev I, Fedyanin M, Polyanskaya E, et al. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO open. 2020;5: e000578.","journal-title":"ESMO open"},{"key":"2173_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/oncolo\/oyad178","volume":"28","author":"KT Chen","year":"2023","unstructured":"Chen KT, Madison R, Moore J, et al. A novel HRD signature is predictive of FOLFIRINOX benefit in metastatic pancreatic cancer. Oncologist. 2023;28:691\u20138.","journal-title":"Oncologist"},{"key":"2173_CR25","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1158\/0008-5472.CAN-05-3546","volume":"66","author":"G Chenevix-Trench","year":"2006","unstructured":"Chenevix-Trench G, Healey S, Lakhani S, et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res. 2006;66:2019\u201327.","journal-title":"Cancer Res"},{"key":"2173_CR26","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1245\/s10434-007-9379-7","volume":"14","author":"F Meric-Bernstam","year":"2007","unstructured":"Meric-Bernstam F. Heterogenic loss of BRCA in breast cancer: the \u201ctwo-hit\u201d hypothesis takes a hit. Ann Surg Oncol. 2007;14:2428\u20139.","journal-title":"Ann Surg Oncol"},{"key":"2173_CR27","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1586\/14737159.2015.1078238","volume":"15","author":"CC Gunderson","year":"2015","unstructured":"Gunderson CC, Moore KN. BRACAnalysis CDx as a companion diagnostic tool for Lynparza. Expert Rev Mol Diagn. 2015;15:1111\u20136.","journal-title":"Expert Rev Mol Diagn"},{"key":"2173_CR28","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s10147-020-01721-x","volume":"25","author":"N Okano","year":"2020","unstructured":"Okano N, Morizane C, Nomura S, et al. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic\/breast\/ovarian\/prostate cancer or personal history of breast\/ovarian\/prostate cancer (FABRIC study). Int J Clin Oncol. 2020;25:1835\u201343.","journal-title":"Int J Clin Oncol"},{"key":"2173_CR29","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381.","journal-title":"Lancet"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02173-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-024-02173-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02173-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T09:14:29Z","timestamp":1738660469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-024-02173-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2173"],"URL":"https:\/\/doi.org\/10.1007\/s00535-024-02173-0","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}